Innovent Biopharmaceutical Technology (hangzhou) Co., Ltd.

This phase 3 trial tests a new drug called IBI354, given with or without another drug (pertuzumab), against the current standard treatment for people with advanced HER2-positive breast cancer that cannot be removed by surgery. The study aims to see if the new combination helps de…

This study tests a new drug called picankibart for people with active psoriatic arthritis, a condition causing joint pain and skin patches. About 222 adults will get either the drug or a placebo to see if it improves joint swelling and tenderness. The goal is to find the best dos…

This study tests a combination of two drugs, IBI310 and sintilimab, as a first treatment for people with advanced liver cancer that cannot be removed by surgery. About 680 participants will receive the combo to see if it shrinks tumors and helps them live longer. The goal is to c…

This study tests a new drug called picankibart in teenagers aged 12 to 18 with moderate to severe plaque psoriasis. The goal is to see if it safely reduces skin plaques by at least 75% compared to a placebo. About 104 participants will receive either the drug or a placebo, and re…